Drugs / Ruzasvir
Ruzasvir
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07272889 | Dec 2025 → Feb 2026 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06911320 | Apr 2025 → May 2026 overdue | impaired renal function disease | Atea Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06921941 | Apr → Jul 2025 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06356194 | Apr → May 2024 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06204679 | Dec 2023 → Aug 2024 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05731843 | Jan → Mar 2023 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02666352 | Jan 2016 → Jan 2017 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02661126 | Jan → Aug 2016 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02076100 | Mar 2014 → Nov 2015 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05904470 | May 2023 → Dec 2024 | chronic hepatitis C virus infection, cirrhosis of liver | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02956629 | Nov 2016 → Dec 2017 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02759315 | May 2016 → Jul 2017 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02613403 | Dec 2015 → Jan 2017 | Flaviviridae infectious disease, hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02332720 | Jan 2015 → Sep 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT02332707 | Jan 2015 → Sep 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07037277 | Jun 2025 → Dec 2026 expected | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868264 | Apr 2025 → Sep 2026 expected | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ruzasvir | “This is a randomized, multicenter, 2-part, open-label trial of the combination regimen of grazoprevir (GZR [MK-5172]; 100mg), uprifosbuvir (UPR [MK-3682]; 450 mg) and ruzasvir...” NCT02613403 ↗16“A Phase 1, Open-Label, Two-Part Study to Evaluate the Effect of a Single Oral Dose of Bemnifosbuvir/Ruzasvir Fixed Dose Combination on the Pharmacokinetics of Digoxin and...” NCT06921941 ↗ “FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.” NCT02661126 ↗ |
| Known as | MK-8408 | “The purpose of this study is to compare the plasma pharmacokinetics (PK) of single doses of MK-3682B, a fixed dose combination (FDC) tablet containing uprifosbuvir (MK-3682) +...” NCT02661126 ↗2“This is a 3-part study of Ruzasvir (MK-8408) for participants with hepatitis C infection.” NCT02076100 ↗ “ruzasvir (RZR [MK-8408]; 60 mg)” NCT02613403 ↗ |
| Known as | RZR | “In clinical trials, the three-drug regimen of ruzasvir (RZR) 60 mg, uprifosbuvir (UPR) 450 mg and grazoprevir 100 mg, with or without ribavirin, has demonstrated promising...” PMID 30739366 ↗ Mar 20194“A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)” NCT06204679 ↗ “Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination” NCT06911320 ↗ “Ruzasvir (RZR; AT-038) Capsules” NCT05904470 ↗ “ruzasvir (RZR [MK-8408]; 60 mg)” NCT02613403 ↗ |
| Action | Inhibit | “ruzasvir (MK-8408; an NS5A inhibitor; 60 mg/day)” PMID 28802814 ↗ Aug 2017 |
| Modality | Other / unclassified | “Ruzasvir (MK-8408, an NS5A inhibitor) and uprifosbuvir (MK-3682, a nonstructural protein 5B nucleotide inhibitor) are highly potent direct-acting antiviral agents” PMID 31108015 ↗ Jul 2019 |
| Route | Oral | “Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.” NCT02076100 ↗ |